{"id":347681,"date":"2025-08-25T12:50:53","date_gmt":"2025-08-25T12:50:53","guid":{"rendered":"https:\/\/pocketoption.com\/blog\/how-to-buy-ovid-therapeutics\/"},"modified":"2025-08-25T12:50:53","modified_gmt":"2025-08-25T12:50:53","slug":"how-to-buy-ovid-therapeutics","status":"publish","type":"post","link":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-ovid-therapeutics\/","title":{"rendered":"Ovid Therapeutics Inc. (OVID) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Ovid Therapeutics Inc. (OVID) Hisse Senedi Yat\u0131r\u0131m\u0131"},"content":{"rendered":"<div id=\"root\"><div id=\"wrap-img-root\">text<\/div><\/div>","protected":false},"excerpt":{"rendered":"<p>text<\/p>\n","protected":false},"author":129,"featured_media":334117,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[12837],"tags":[40],"class_list":["post-347681","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-signal","tag-signal"],"acf":{"h1":"Ovid Therapeutics Inc. (OVID) Hisseleri Nas\u0131l Al\u0131n\u0131r - Ovid Therapeutics Inc. (OVID) Hisse Senedi Yat\u0131r\u0131m\u0131","h1_source":{"label":"H1","type":"text","formatted_value":"Ovid Therapeutics Inc. (OVID) Hisseleri Nas\u0131l Al\u0131n\u0131r - Ovid Therapeutics Inc. (OVID) Hisse Senedi Yat\u0131r\u0131m\u0131"},"description":"Fiyat tahminleri, riskler ve ad\u0131m ad\u0131m sat\u0131n alma rehberi dahil olmak \u00fczere tam yat\u0131r\u0131m analizimizle Ovid Therapeutics Inc. (OVID) hisselerinin nas\u0131l al\u0131naca\u011f\u0131n\u0131 \u00f6\u011frenin.","description_source":{"label":"Description","type":"textarea","formatted_value":"Fiyat tahminleri, riskler ve ad\u0131m ad\u0131m sat\u0131n alma rehberi dahil olmak \u00fczere tam yat\u0131r\u0131m analizimizle Ovid Therapeutics Inc. (OVID) hisselerinin nas\u0131l al\u0131naca\u011f\u0131n\u0131 \u00f6\u011frenin."},"intro":"N\u00f6rolojik t\u0131p alan\u0131nda \u00f6nc\u00fc bir d\u00fcnyaya yat\u0131r\u0131m yapmay\u0131 m\u0131 d\u00fc\u015f\u00fcn\u00fcyorsunuz? Ovid Therapeutics Inc. (OVID), biyoteknoloji sekt\u00f6r\u00fcndeki en heyecan verici ve volatil f\u0131rsatlardan birini temsil ediyor. Bu \u015firket, d\u00fcnya \u00e7ap\u0131nda milyonlarca insan\u0131 etkileyen beyin hastal\u0131klar\u0131 i\u00e7in tedaviler geli\u015ftirerek hem hastalar hem de yat\u0131r\u0131mc\u0131lar i\u00e7in potansiyel bir oyun de\u011fi\u015ftirici konumunda. Bu hisse senedini bu kadar \u00e7ekici k\u0131lan unsurlar\u0131 ve portf\u00f6y\u00fcn\u00fcze stratejik olarak nas\u0131l ekleyebilece\u011finizi ke\u015ffedelim.","intro_source":{"label":"Intro","type":"text","formatted_value":"N\u00f6rolojik t\u0131p alan\u0131nda \u00f6nc\u00fc bir d\u00fcnyaya yat\u0131r\u0131m yapmay\u0131 m\u0131 d\u00fc\u015f\u00fcn\u00fcyorsunuz? Ovid Therapeutics Inc. (OVID), biyoteknoloji sekt\u00f6r\u00fcndeki en heyecan verici ve volatil f\u0131rsatlardan birini temsil ediyor. Bu \u015firket, d\u00fcnya \u00e7ap\u0131nda milyonlarca insan\u0131 etkileyen beyin hastal\u0131klar\u0131 i\u00e7in tedaviler geli\u015ftirerek hem hastalar hem de yat\u0131r\u0131mc\u0131lar i\u00e7in potansiyel bir oyun de\u011fi\u015ftirici konumunda. Bu hisse senedini bu kadar \u00e7ekici k\u0131lan unsurlar\u0131 ve portf\u00f6y\u00fcn\u00fcze stratejik olarak nas\u0131l ekleyebilece\u011finizi ke\u015ffedelim."},"body_html":"<h2>\ud83d\udcc8 Ovid Therapeutics Hissesi: G\u00fcncel Fiyat ve Kritik Tarihler<\/h2> <p>25 A\u011fustos 2025 itibar\u0131yla, Ovid Therapeutics Inc. (OVID) hissesi <strong>1,03 $<\/strong> fiyatla i\u015flem g\u00f6r\u00fcyor. Ancak takviminize not edin: <strong>Kas\u0131m 2025<\/strong> bu hisse i\u00e7in patlay\u0131c\u0131 olabilir. \u015eirketin bir sonraki kazan\u00e7 raporunu a\u00e7\u0131klamas\u0131 bekleniyor ve son tarihlere bak\u0131ld\u0131\u011f\u0131nda, bu t\u00fcr olaylar OVID \u00fczerinde dramatik hareketlere neden oluyor.<\/p> <h3>Kazan\u00e7 Raporlar\u0131 OVID Hissesini Nas\u0131l Etkiler?<\/h3> <p>13 A\u011fustos 2025'teki en son kazan\u00e7 raporu piyasada \u015fok etkisi yaratt\u0131. \u015eirket, 6,27 milyon $ gelir bildirdi\u2014ge\u00e7en y\u0131l\u0131n ayn\u0131 d\u00f6nemine g\u00f6re muazzam bir <strong>%3.611 art\u0131\u015f<\/strong>! Ar-Ge harcamalar\u0131n\u0131n artmas\u0131 nedeniyle 4,68 milyon $ net zarar a\u00e7\u0131klamas\u0131na ra\u011fmen, hisse senedi sonraki i\u015flem seans\u0131nda inan\u0131lmaz bir <strong>%52,61 art\u0131\u015f<\/strong> g\u00f6sterdi (<a href=\"https:\/\/www.ainvest.com\/news\/ovid-therapeutics-reports-q2-2025-financials-7mln-royalty-deal-q3-2025-results-expected-2508\/\">AInvest Raporu<\/a>).<\/p> <p>Bu model yeni de\u011fil. OVID gibi biyoteknoloji hisseleri klinik deneme sonu\u00e7lar\u0131 ve kazan\u00e7 s\u00fcrprizlerine ba\u011fl\u0131 olarak y\u00fckselip d\u00fc\u015fer. Kas\u0131m ay\u0131ndaki rapor da \u00f6zellikle OV329 tedavisi i\u00e7in beklenen \u00f6nemli veri a\u00e7\u0131klamalar\u0131yla ayn\u0131 derecede dramatik olabilir.<\/p> [cta_green text=\"Ticarete Ba\u015fla\"]<h2>\ud83d\udd0d 6 Ayl\u0131k Fiyat Yolculu\u011fu: Dalgalarla Dolu Bir S\u00fcr\u00fc\u015f<\/h2> <p>OVID'in son alt\u0131 aydaki fiyat hareketleri nefes kesici oldu:<\/p> <ul> <li><strong>\u015eubat-Mart 2025<\/strong>: Hisse senedi 0,60-0,70 $ aral\u0131\u011f\u0131nda i\u015flem g\u00f6rd\u00fc, tipik biyoteknoloji volatilitesi g\u00f6sterdi<\/li> <li><strong>Nisan-Haziran 2025<\/strong>: B\u00fcy\u00fck kataliz\u00f6rler \u00f6ncesi klasik \"bekleme d\u00f6nemi\" olarak 0,24-0,40 $ aral\u0131\u011f\u0131na kademeli d\u00fc\u015f\u00fc\u015f<\/li> <li><strong>Temmuz 2025<\/strong>: G\u00fcnl\u00fck volatilite ortalamas\u0131 <strong>%11,15<\/strong> olan patlay\u0131c\u0131 hareket, %14,79 g\u00fcnl\u00fck dalgalanma dahil<\/li> <li><strong>A\u011fustos 2025<\/strong>: B\u00fcy\u00fck \u00e7\u0131k\u0131\u015f\u2014pozitif kazan\u00e7 ve klinik g\u00fcncellemeler sonras\u0131 bir ayda <strong>%163,59<\/strong> art\u0131\u015f<\/li> <\/ul> <p>Bu kadar dramatik hareketlerin sebebi nedir? OVID, biyoteknoloji yat\u0131r\u0131m\u0131n\u0131n saf \u00f6z\u00fcn\u00fc temsil ediyor: y\u00fcksek risk, y\u00fcksek getiri. Hisse bu d\u00f6nemde 52 haftal\u0131k en d\u00fc\u015f\u00fck <strong>0,24 $<\/strong> ve en y\u00fcksek <strong>1,47 $<\/strong> seviyelerine ula\u015ft\u0131, a\u015f\u0131r\u0131 aral\u0131k potansiyelini g\u00f6steriyor (<a href=\"https:\/\/stockinvest.us\/stock\/OVID\">StockInvest Verileri<\/a>).<\/p> <h2>\ud83d\udd2e Fiyat Tahmini: 2025-2030 G\u00f6r\u00fcn\u00fcm\u00fc<\/h2> <ul> <li><strong>2025 Y\u0131l Sonu<\/strong>: 3,10-7,14 $ aral\u0131\u011f\u0131 (potansiyel %200-578 y\u00fckseli\u015f) \u2192 <strong>G\u00dc\u00c7L\u00dc AL<\/strong><br> Analistler b\u00fcy\u00fck \u00f6l\u00e7\u00fcde iyimser, ortalama fiyat hedefi 3,10 $ ve teknik modeller 7,14 $'a kadar tahmin ediyor (<a href=\"https:\/\/stockscan.io\/stocks\/OVID\/forecast\">StockScan Tahmini<\/a>). Ana kataliz\u00f6r? 2025 3. \u00e7eyrekte beklenen OV329 Faz 1 verileri.<\/li> <li><strong>2026 Tahmini<\/strong>: 0,495-3,50 $ aral\u0131\u011f\u0131<br> Buradaki farkl\u0131l\u0131k biyoteknolojinin ikili do\u011fas\u0131n\u0131 yans\u0131t\u0131yor\u2014ya klinik denemeler ba\u015far\u0131l\u0131 olur (y\u00fcksek aral\u0131k) ya da zorluklarla kar\u015f\u0131la\u015f\u0131r (d\u00fc\u015f\u00fck aral\u0131k).<\/li> <li><strong>2028 Projeksiyonu<\/strong>: 0,225-1,00 $<br> Uzun vadeli modeller muhafazakar tahminler g\u00f6steriyor, ancak ba\u015far\u0131l\u0131 ila\u00e7 onaylar\u0131 bu g\u00f6r\u00fcn\u00fcm\u00fc dramatik \u015fekilde de\u011fi\u015ftirebilir.<\/li> <li><strong>2030 G\u00f6r\u00fcn\u00fcm\u00fc<\/strong>: Olduk\u00e7a spek\u00fclatif<br> 2030'a kadar, OVID'in \u00fcr\u00fcn hatt\u0131 en az bir onayl\u0131 ila\u00e7 sunarsa, hisse \u00f6nemli \u00f6l\u00e7\u00fcde katlanabilir. Ancak bu tahminin en riskli k\u0131sm\u0131 olarak kal\u0131yor.<\/li> <\/ul> <h2>\u26a0\ufe0f Temel Riskler ve Olumlu \u0130\u015faretler<\/h2> <h3>Dikkate Al\u0131nmas\u0131 Gereken Riskler:<\/h3> <ul> <li><strong>Nakit t\u00fcketimi<\/strong>: 38,3 milyon $ nakit pozisyonuna ra\u011fmen bir y\u0131ldan az nakit \u00f6mr\u00fc<\/li> <li><strong>Klinik deneme ba\u015far\u0131s\u0131zl\u0131klar\u0131<\/strong>: OV329 i\u00e7in Faz 1 verileri yat\u0131r\u0131mc\u0131lar\u0131 hayal k\u0131r\u0131kl\u0131\u011f\u0131na u\u011fratabilir<\/li> <li><strong>A\u015f\u0131r\u0131 volatilite<\/strong>: %11,15 ortalama g\u00fcnl\u00fck dalgalanmalar her yat\u0131r\u0131mc\u0131n\u0131n sinirlerini zorlayabilir<\/li> <li><strong>Hisse seyrelme riski<\/strong>: Operasyonlar\u0131 finanse etmek i\u00e7in ek hisse arz\u0131 olas\u0131l\u0131\u011f\u0131 y\u00fcksek<\/li> <\/ul> <h3>2025 \u0130\u00e7in Ye\u015fil I\u015f\u0131klar:<\/h3> <ul> <li><strong>Gelir patlamas\u0131<\/strong>: Y\u0131ll\u0131k %3.611 b\u00fcy\u00fcme i\u015f modeli potansiyelini g\u00f6steriyor<\/li> <li><strong>\u00dcr\u00fcn hatt\u0131 ilerlemesi<\/strong>: OV329 Faz 1 verileri 2025 3. \u00e7eyrekte bekleniyor\u2014b\u00fcy\u00fck kataliz\u00f6r<\/li> <li><strong>Stratejik anla\u015fmalar<\/strong>: Immedica ile 7 milyon $'l\u0131k telif hakk\u0131 anla\u015fmas\u0131 nakit \u00f6mr\u00fcn\u00fc uzat\u0131yor<\/li> <li><strong>Sekt\u00f6r r\u00fczgarlar\u0131<\/strong>: Merkezi sinir sistemi bozukluklar\u0131 tedavileri 150 milyar $'dan fazla pazar f\u0131rsat\u0131 sunuyor<\/li> <\/ul> <h2>\ud83d\udee1\ufe0f Yeni Ba\u015flayan Bir T\u00fcccar Bug\u00fcn Ne Yapmal\u0131?<\/h2> <ol> <li><strong>K\u00fc\u00e7\u00fck ba\u015flay\u0131n<\/strong>: Portf\u00f6y\u00fcn\u00fcz\u00fcn %2-5'inden fazlas\u0131n\u0131 OVID gibi y\u00fcksek riskli biyoteknolojiye ay\u0131rmay\u0131n<\/li> <li><strong>Dolar maliyeti ortalamas\u0131 yap\u0131n<\/strong>: Tek seferde b\u00fcy\u00fck al\u0131m yerine k\u00fc\u00e7\u00fck par\u00e7alar halinde sat\u0131n al\u0131n<\/li> <li><strong>Stop-loss belirleyin<\/strong>: A\u015f\u0131r\u0131 d\u00fc\u015f\u00fc\u015f volatilitesine kar\u015f\u0131 kendinizi koruyun<\/li> <li><strong>Kataliz\u00f6rleri takip edin<\/strong>: Kas\u0131m 2025 kazan\u00e7 ve 3. \u00e7eyrek klinik veri tarihlerini i\u015faretleyin<\/li> <\/ol> <p>Espiriyle: \"OVID ticareti yapmak, bir n\u00f6robilimciyle \u00e7\u0131kmak gibidir\u2014parlak potansiyel, duygusal olarak \u00f6ng\u00f6r\u00fclemez ve g\u00fc\u00e7l\u00fc mide ilac\u0131 gerektirir!\"<\/p> <h2>\u2705 Ovid Therapeutics Inc. (OVID) Hisseleri Nas\u0131l Al\u0131n\u0131r - Ad\u0131m Ad\u0131m<\/h2> <table> <thead> <tr><th>Ad\u0131m<\/th><th>\u0130\u015flem<\/th><th>Neden \u00d6nemli<\/th><\/tr> <\/thead> <tbody> <tr><td>1<\/td><td>Bir ticaret platformu se\u00e7in<\/td><td>NASDAQ eri\u015fimi ve OVID bulunabilirli\u011fi sunmas\u0131na dikkat edin<\/td><\/tr> <tr><td>2<\/td><td>Hesap do\u011frulamas\u0131n\u0131 tamamlay\u0131n<\/td><td>\u00c7o\u011fu platform kimlik ve adres kan\u0131t\u0131 ister<\/td><\/tr> <tr><td>3<\/td><td>Fon yat\u0131r\u0131n<\/td><td>Kaybetmeyi g\u00f6ze alabilece\u011finiz bir miktarla ba\u015flay\u0131n<\/td><\/tr> <tr><td>4<\/td><td>\"OVID\" aramas\u0131 yap\u0131n<\/td><td>Sadece \u015firket ad\u0131 de\u011fil, borsa sembol\u00fcn\u00fc kullan\u0131n<\/td><\/tr> <tr><td>5<\/td><td>Emir t\u00fcr\u00fcn\u00fc se\u00e7in<\/td><td>Volatil hisselerde giri\u015f fiyat\u0131n\u0131z\u0131 kontrol etmek i\u00e7in limit emirleri kullan\u0131n<\/td><\/tr> <tr><td>6<\/td><td>\u0130nceleyin ve onaylay\u0131n<\/td><td>\u0130\u015flem yapmadan \u00f6nce miktar ve fiyat\u0131 \u00e7ift kontrol edin<\/td><\/tr> <tr><td>7<\/td><td>Pozisyonunuzu takip edin<\/td><td>B\u00fcy\u00fck hareket seviyeleri i\u00e7in fiyat uyar\u0131lar\u0131 ayarlay\u0131n<\/td><\/tr> <\/tbody> <\/table> <h2>\ud83d\udca1 Neden Pocket Option Yeni Biyoteknoloji Yat\u0131r\u0131mc\u0131lar\u0131 \u0130\u00e7in Uygun?<\/h2> <p>OVID gibi volatil biyoteknoloji hisselerine ad\u0131m atmak isteyenler i\u00e7in Pocket Option birka\u00e7 avantaj sunar:<\/p> <ul> <li><strong>Sadece 5 $ minimum depozito<\/strong>\u2014k\u00fc\u00e7\u00fck miktarlarla stratejileri test etmek i\u00e7in ideal<\/li> <li><strong>Y\u0131ld\u0131r\u0131m h\u0131z\u0131nda do\u011frulama<\/strong>\u2014temel belgelerle dakikalar i\u00e7inde ticarete ba\u015flay\u0131n<\/li> <li><strong>\u00c7e\u015fitli para \u00e7ekme se\u00e7enekleri<\/strong>\u2014k\u00e2rlar\u0131n\u0131z\u0131 birden fazla uygun y\u00f6ntemle \u00e7ekin<\/li> <\/ul> <p>Platformun kullan\u0131c\u0131 dostu aray\u00fcz\u00fc, biyoteknoloji volatilitesinde yeni olanlar i\u00e7in navigasyonu \u00e7ok daha az korkutucu hale getiriyor.<\/p> <h2>\ud83c\udf0d 2025'te Ovid Therapeutics: N\u00f6robilimde Yenilik\u00e7i<\/h2> <p>Ovid Therapeutics, onlarca y\u0131ld\u0131r doktorlar\u0131 zorlayan durumlar i\u00e7in \u00e7\u0131\u011f\u0131r a\u00e7an tedaviler geli\u015ftirerek n\u00f6rolojik t\u0131bb\u0131n \u00f6n saflar\u0131nda yer al\u0131yor. \u015eirketin GABA aminotransferaz inhibit\u00f6rleri ve KCC2 aktivat\u00f6rlerine odaklanmas\u0131, MSS alan\u0131ndaki en umut verici bilimlerden baz\u0131lar\u0131n\u0131 temsil ediyor.<\/p> <p>Yakla\u015f\u0131k 60 milyon $ piyasa de\u011feriyle OVID, b\u00fcy\u00fck potansiyele sahip k\u00fc\u00e7\u00fck \u00f6l\u00e7ekli bir de\u011fer olarak kal\u0131yor. \u015eirketin son gelir patlamas\u0131\u2014bir y\u0131lda 0,17 milyon $'dan 6,27 milyon $'a\u2014i\u015f modelinin ivme kazand\u0131\u011f\u0131n\u0131 g\u00f6steriyor (<a href=\"https:\/\/investors.ovidrx.com\/news\/news-details\/2025\/Ovid-Therapeutics-Reports-Business-Updates-and-Second-Quarter-2025-Financial-Results\/default.aspx\">Resmi Yat\u0131r\u0131mc\u0131 Raporu<\/a>).<\/p> <p><strong>\u0130lgin\u00e7 Ger\u00e7ek<\/strong>: 2025'te Ovid'in ara\u015ft\u0131rma ekibi, lider bile\u015fikleri OV329'un sadece n\u00f6betleri azaltmakla kalmay\u0131p, ayn\u0131 zamanda preklinik modellerde bili\u015fsel fonksiyonu da iyile\u015ftirdi\u011fini ke\u015ffetti\u2014epilepsi tedavisinde devrim yaratabilecek potansiyel \u00e7ift fayda!<\/p>","body_html_source":{"label":"Body HTML","type":"wysiwyg","formatted_value":"<h2>\ud83d\udcc8 Ovid Therapeutics Hissesi: G\u00fcncel Fiyat ve Kritik Tarihler<\/h2>\n<p>25 A\u011fustos 2025 itibar\u0131yla, Ovid Therapeutics Inc. (OVID) hissesi <strong>1,03 $<\/strong> fiyatla i\u015flem g\u00f6r\u00fcyor. Ancak takviminize not edin: <strong>Kas\u0131m 2025<\/strong> bu hisse i\u00e7in patlay\u0131c\u0131 olabilir. \u015eirketin bir sonraki kazan\u00e7 raporunu a\u00e7\u0131klamas\u0131 bekleniyor ve son tarihlere bak\u0131ld\u0131\u011f\u0131nda, bu t\u00fcr olaylar OVID \u00fczerinde dramatik hareketlere neden oluyor.<\/p>\n<h3>Kazan\u00e7 Raporlar\u0131 OVID Hissesini Nas\u0131l Etkiler?<\/h3>\n<p>13 A\u011fustos 2025&#8217;teki en son kazan\u00e7 raporu piyasada \u015fok etkisi yaratt\u0131. \u015eirket, 6,27 milyon $ gelir bildirdi\u2014ge\u00e7en y\u0131l\u0131n ayn\u0131 d\u00f6nemine g\u00f6re muazzam bir <strong>%3.611 art\u0131\u015f<\/strong>! Ar-Ge harcamalar\u0131n\u0131n artmas\u0131 nedeniyle 4,68 milyon $ net zarar a\u00e7\u0131klamas\u0131na ra\u011fmen, hisse senedi sonraki i\u015flem seans\u0131nda inan\u0131lmaz bir <strong>%52,61 art\u0131\u015f<\/strong> g\u00f6sterdi (<a href=\"https:\/\/www.ainvest.com\/news\/ovid-therapeutics-reports-q2-2025-financials-7mln-royalty-deal-q3-2025-results-expected-2508\/\">AInvest Raporu<\/a>).<\/p>\n<p>Bu model yeni de\u011fil. OVID gibi biyoteknoloji hisseleri klinik deneme sonu\u00e7lar\u0131 ve kazan\u00e7 s\u00fcrprizlerine ba\u011fl\u0131 olarak y\u00fckselip d\u00fc\u015fer. Kas\u0131m ay\u0131ndaki rapor da \u00f6zellikle OV329 tedavisi i\u00e7in beklenen \u00f6nemli veri a\u00e7\u0131klamalar\u0131yla ayn\u0131 derecede dramatik olabilir.<\/p>\n<div class=\"po-container po-container_width_article\">\n   <div class=\"po-cta-green__wrap\">\n      <a href=\"https:\/\/pocketoption.com\/tr\/register\/\" class=\"po-cta-green\">Ticarete Ba\u015fla\n         <span class=\"po-cta-green__icon\">\n            <svg width=\"24\" height=\"24\" fill=\"none\" aria-hidden=\"true\">\n               <use href=\"#svg-arrow-cta\"><\/use>\n            <\/svg>\n         <\/span>\n      <\/a>\n   <\/div>\n<\/div>\n<h2>\ud83d\udd0d 6 Ayl\u0131k Fiyat Yolculu\u011fu: Dalgalarla Dolu Bir S\u00fcr\u00fc\u015f<\/h2>\n<p>OVID&#8217;in son alt\u0131 aydaki fiyat hareketleri nefes kesici oldu:<\/p>\n<ul>\n<li><strong>\u015eubat-Mart 2025<\/strong>: Hisse senedi 0,60-0,70 $ aral\u0131\u011f\u0131nda i\u015flem g\u00f6rd\u00fc, tipik biyoteknoloji volatilitesi g\u00f6sterdi<\/li>\n<li><strong>Nisan-Haziran 2025<\/strong>: B\u00fcy\u00fck kataliz\u00f6rler \u00f6ncesi klasik &#8220;bekleme d\u00f6nemi&#8221; olarak 0,24-0,40 $ aral\u0131\u011f\u0131na kademeli d\u00fc\u015f\u00fc\u015f<\/li>\n<li><strong>Temmuz 2025<\/strong>: G\u00fcnl\u00fck volatilite ortalamas\u0131 <strong>%11,15<\/strong> olan patlay\u0131c\u0131 hareket, %14,79 g\u00fcnl\u00fck dalgalanma dahil<\/li>\n<li><strong>A\u011fustos 2025<\/strong>: B\u00fcy\u00fck \u00e7\u0131k\u0131\u015f\u2014pozitif kazan\u00e7 ve klinik g\u00fcncellemeler sonras\u0131 bir ayda <strong>%163,59<\/strong> art\u0131\u015f<\/li>\n<\/ul>\n<p>Bu kadar dramatik hareketlerin sebebi nedir? OVID, biyoteknoloji yat\u0131r\u0131m\u0131n\u0131n saf \u00f6z\u00fcn\u00fc temsil ediyor: y\u00fcksek risk, y\u00fcksek getiri. Hisse bu d\u00f6nemde 52 haftal\u0131k en d\u00fc\u015f\u00fck <strong>0,24 $<\/strong> ve en y\u00fcksek <strong>1,47 $<\/strong> seviyelerine ula\u015ft\u0131, a\u015f\u0131r\u0131 aral\u0131k potansiyelini g\u00f6steriyor (<a href=\"https:\/\/stockinvest.us\/stock\/OVID\">StockInvest Verileri<\/a>).<\/p>\n<h2>\ud83d\udd2e Fiyat Tahmini: 2025-2030 G\u00f6r\u00fcn\u00fcm\u00fc<\/h2>\n<ul>\n<li><strong>2025 Y\u0131l Sonu<\/strong>: 3,10-7,14 $ aral\u0131\u011f\u0131 (potansiyel %200-578 y\u00fckseli\u015f) \u2192 <strong>G\u00dc\u00c7L\u00dc AL<\/strong><br \/> Analistler b\u00fcy\u00fck \u00f6l\u00e7\u00fcde iyimser, ortalama fiyat hedefi 3,10 $ ve teknik modeller 7,14 $&#8217;a kadar tahmin ediyor (<a href=\"https:\/\/stockscan.io\/stocks\/OVID\/forecast\">StockScan Tahmini<\/a>). Ana kataliz\u00f6r? 2025 3. \u00e7eyrekte beklenen OV329 Faz 1 verileri.<\/li>\n<li><strong>2026 Tahmini<\/strong>: 0,495-3,50 $ aral\u0131\u011f\u0131<br \/> Buradaki farkl\u0131l\u0131k biyoteknolojinin ikili do\u011fas\u0131n\u0131 yans\u0131t\u0131yor\u2014ya klinik denemeler ba\u015far\u0131l\u0131 olur (y\u00fcksek aral\u0131k) ya da zorluklarla kar\u015f\u0131la\u015f\u0131r (d\u00fc\u015f\u00fck aral\u0131k).<\/li>\n<li><strong>2028 Projeksiyonu<\/strong>: 0,225-1,00 $<br \/> Uzun vadeli modeller muhafazakar tahminler g\u00f6steriyor, ancak ba\u015far\u0131l\u0131 ila\u00e7 onaylar\u0131 bu g\u00f6r\u00fcn\u00fcm\u00fc dramatik \u015fekilde de\u011fi\u015ftirebilir.<\/li>\n<li><strong>2030 G\u00f6r\u00fcn\u00fcm\u00fc<\/strong>: Olduk\u00e7a spek\u00fclatif<br \/> 2030&#8217;a kadar, OVID&#8217;in \u00fcr\u00fcn hatt\u0131 en az bir onayl\u0131 ila\u00e7 sunarsa, hisse \u00f6nemli \u00f6l\u00e7\u00fcde katlanabilir. Ancak bu tahminin en riskli k\u0131sm\u0131 olarak kal\u0131yor.<\/li>\n<\/ul>\n<h2>\u26a0\ufe0f Temel Riskler ve Olumlu \u0130\u015faretler<\/h2>\n<h3>Dikkate Al\u0131nmas\u0131 Gereken Riskler:<\/h3>\n<ul>\n<li><strong>Nakit t\u00fcketimi<\/strong>: 38,3 milyon $ nakit pozisyonuna ra\u011fmen bir y\u0131ldan az nakit \u00f6mr\u00fc<\/li>\n<li><strong>Klinik deneme ba\u015far\u0131s\u0131zl\u0131klar\u0131<\/strong>: OV329 i\u00e7in Faz 1 verileri yat\u0131r\u0131mc\u0131lar\u0131 hayal k\u0131r\u0131kl\u0131\u011f\u0131na u\u011fratabilir<\/li>\n<li><strong>A\u015f\u0131r\u0131 volatilite<\/strong>: %11,15 ortalama g\u00fcnl\u00fck dalgalanmalar her yat\u0131r\u0131mc\u0131n\u0131n sinirlerini zorlayabilir<\/li>\n<li><strong>Hisse seyrelme riski<\/strong>: Operasyonlar\u0131 finanse etmek i\u00e7in ek hisse arz\u0131 olas\u0131l\u0131\u011f\u0131 y\u00fcksek<\/li>\n<\/ul>\n<h3>2025 \u0130\u00e7in Ye\u015fil I\u015f\u0131klar:<\/h3>\n<ul>\n<li><strong>Gelir patlamas\u0131<\/strong>: Y\u0131ll\u0131k %3.611 b\u00fcy\u00fcme i\u015f modeli potansiyelini g\u00f6steriyor<\/li>\n<li><strong>\u00dcr\u00fcn hatt\u0131 ilerlemesi<\/strong>: OV329 Faz 1 verileri 2025 3. \u00e7eyrekte bekleniyor\u2014b\u00fcy\u00fck kataliz\u00f6r<\/li>\n<li><strong>Stratejik anla\u015fmalar<\/strong>: Immedica ile 7 milyon $&#8217;l\u0131k telif hakk\u0131 anla\u015fmas\u0131 nakit \u00f6mr\u00fcn\u00fc uzat\u0131yor<\/li>\n<li><strong>Sekt\u00f6r r\u00fczgarlar\u0131<\/strong>: Merkezi sinir sistemi bozukluklar\u0131 tedavileri 150 milyar $&#8217;dan fazla pazar f\u0131rsat\u0131 sunuyor<\/li>\n<\/ul>\n<h2>\ud83d\udee1\ufe0f Yeni Ba\u015flayan Bir T\u00fcccar Bug\u00fcn Ne Yapmal\u0131?<\/h2>\n<ol>\n<li><strong>K\u00fc\u00e7\u00fck ba\u015flay\u0131n<\/strong>: Portf\u00f6y\u00fcn\u00fcz\u00fcn %2-5&#8217;inden fazlas\u0131n\u0131 OVID gibi y\u00fcksek riskli biyoteknolojiye ay\u0131rmay\u0131n<\/li>\n<li><strong>Dolar maliyeti ortalamas\u0131 yap\u0131n<\/strong>: Tek seferde b\u00fcy\u00fck al\u0131m yerine k\u00fc\u00e7\u00fck par\u00e7alar halinde sat\u0131n al\u0131n<\/li>\n<li><strong>Stop-loss belirleyin<\/strong>: A\u015f\u0131r\u0131 d\u00fc\u015f\u00fc\u015f volatilitesine kar\u015f\u0131 kendinizi koruyun<\/li>\n<li><strong>Kataliz\u00f6rleri takip edin<\/strong>: Kas\u0131m 2025 kazan\u00e7 ve 3. \u00e7eyrek klinik veri tarihlerini i\u015faretleyin<\/li>\n<\/ol>\n<p>Espiriyle: &#8220;OVID ticareti yapmak, bir n\u00f6robilimciyle \u00e7\u0131kmak gibidir\u2014parlak potansiyel, duygusal olarak \u00f6ng\u00f6r\u00fclemez ve g\u00fc\u00e7l\u00fc mide ilac\u0131 gerektirir!&#8221;<\/p>\n<h2>\u2705 Ovid Therapeutics Inc. (OVID) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Ad\u0131m Ad\u0131m<\/h2>\n<table>\n<thead>\n<tr>\n<th>Ad\u0131m<\/th>\n<th>\u0130\u015flem<\/th>\n<th>Neden \u00d6nemli<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>1<\/td>\n<td>Bir ticaret platformu se\u00e7in<\/td>\n<td>NASDAQ eri\u015fimi ve OVID bulunabilirli\u011fi sunmas\u0131na dikkat edin<\/td>\n<\/tr>\n<tr>\n<td>2<\/td>\n<td>Hesap do\u011frulamas\u0131n\u0131 tamamlay\u0131n<\/td>\n<td>\u00c7o\u011fu platform kimlik ve adres kan\u0131t\u0131 ister<\/td>\n<\/tr>\n<tr>\n<td>3<\/td>\n<td>Fon yat\u0131r\u0131n<\/td>\n<td>Kaybetmeyi g\u00f6ze alabilece\u011finiz bir miktarla ba\u015flay\u0131n<\/td>\n<\/tr>\n<tr>\n<td>4<\/td>\n<td>&#8220;OVID&#8221; aramas\u0131 yap\u0131n<\/td>\n<td>Sadece \u015firket ad\u0131 de\u011fil, borsa sembol\u00fcn\u00fc kullan\u0131n<\/td>\n<\/tr>\n<tr>\n<td>5<\/td>\n<td>Emir t\u00fcr\u00fcn\u00fc se\u00e7in<\/td>\n<td>Volatil hisselerde giri\u015f fiyat\u0131n\u0131z\u0131 kontrol etmek i\u00e7in limit emirleri kullan\u0131n<\/td>\n<\/tr>\n<tr>\n<td>6<\/td>\n<td>\u0130nceleyin ve onaylay\u0131n<\/td>\n<td>\u0130\u015flem yapmadan \u00f6nce miktar ve fiyat\u0131 \u00e7ift kontrol edin<\/td>\n<\/tr>\n<tr>\n<td>7<\/td>\n<td>Pozisyonunuzu takip edin<\/td>\n<td>B\u00fcy\u00fck hareket seviyeleri i\u00e7in fiyat uyar\u0131lar\u0131 ayarlay\u0131n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2>\ud83d\udca1 Neden Pocket Option Yeni Biyoteknoloji Yat\u0131r\u0131mc\u0131lar\u0131 \u0130\u00e7in Uygun?<\/h2>\n<p>OVID gibi volatil biyoteknoloji hisselerine ad\u0131m atmak isteyenler i\u00e7in Pocket Option birka\u00e7 avantaj sunar:<\/p>\n<ul>\n<li><strong>Sadece 5 $ minimum depozito<\/strong>\u2014k\u00fc\u00e7\u00fck miktarlarla stratejileri test etmek i\u00e7in ideal<\/li>\n<li><strong>Y\u0131ld\u0131r\u0131m h\u0131z\u0131nda do\u011frulama<\/strong>\u2014temel belgelerle dakikalar i\u00e7inde ticarete ba\u015flay\u0131n<\/li>\n<li><strong>\u00c7e\u015fitli para \u00e7ekme se\u00e7enekleri<\/strong>\u2014k\u00e2rlar\u0131n\u0131z\u0131 birden fazla uygun y\u00f6ntemle \u00e7ekin<\/li>\n<\/ul>\n<p>Platformun kullan\u0131c\u0131 dostu aray\u00fcz\u00fc, biyoteknoloji volatilitesinde yeni olanlar i\u00e7in navigasyonu \u00e7ok daha az korkutucu hale getiriyor.<\/p>\n<h2>\ud83c\udf0d 2025&#8217;te Ovid Therapeutics: N\u00f6robilimde Yenilik\u00e7i<\/h2>\n<p>Ovid Therapeutics, onlarca y\u0131ld\u0131r doktorlar\u0131 zorlayan durumlar i\u00e7in \u00e7\u0131\u011f\u0131r a\u00e7an tedaviler geli\u015ftirerek n\u00f6rolojik t\u0131bb\u0131n \u00f6n saflar\u0131nda yer al\u0131yor. \u015eirketin GABA aminotransferaz inhibit\u00f6rleri ve KCC2 aktivat\u00f6rlerine odaklanmas\u0131, MSS alan\u0131ndaki en umut verici bilimlerden baz\u0131lar\u0131n\u0131 temsil ediyor.<\/p>\n<p>Yakla\u015f\u0131k 60 milyon $ piyasa de\u011feriyle OVID, b\u00fcy\u00fck potansiyele sahip k\u00fc\u00e7\u00fck \u00f6l\u00e7ekli bir de\u011fer olarak kal\u0131yor. \u015eirketin son gelir patlamas\u0131\u2014bir y\u0131lda 0,17 milyon $&#8217;dan 6,27 milyon $&#8217;a\u2014i\u015f modelinin ivme kazand\u0131\u011f\u0131n\u0131 g\u00f6steriyor (<a href=\"https:\/\/investors.ovidrx.com\/news\/news-details\/2025\/Ovid-Therapeutics-Reports-Business-Updates-and-Second-Quarter-2025-Financial-Results\/default.aspx\">Resmi Yat\u0131r\u0131mc\u0131 Raporu<\/a>).<\/p>\n<p><strong>\u0130lgin\u00e7 Ger\u00e7ek<\/strong>: 2025&#8217;te Ovid&#8217;in ara\u015ft\u0131rma ekibi, lider bile\u015fikleri OV329&#8217;un sadece n\u00f6betleri azaltmakla kalmay\u0131p, ayn\u0131 zamanda preklinik modellerde bili\u015fsel fonksiyonu da iyile\u015ftirdi\u011fini ke\u015ffetti\u2014epilepsi tedavisinde devrim yaratabilecek potansiyel \u00e7ift fayda!<\/p>\n"},"faq":[{"question":"Ovid Therapeutics hisseleri nereden al\u0131nabilir?","answer":"Ovid Therapeutics hisseleri NASDAQ borsas\u0131nda i\u015flem g\u00f6rmektedir ve bir\u00e7ok \u00e7evrimi\u00e7i arac\u0131 kurum ve ticaret platformu \u00fczerinden sat\u0131n al\u0131nabilir."},{"question":"OVID hissesi almak i\u00e7in minimum yat\u0131r\u0131m tutar\u0131 nedir?","answer":"Minimum yat\u0131r\u0131m tutar\u0131 platforma g\u00f6re de\u011fi\u015fir ancak Pocket Option gibi baz\u0131 platformlarda sadece 5 $ depozito ile ba\u015flayabilirsiniz."},{"question":"Ovid Therapeutics hisselerinin riskleri nelerdir?","answer":"Ba\u015fl\u0131ca riskler aras\u0131nda nakit t\u00fcketimi, klinik deneme ba\u015far\u0131s\u0131zl\u0131klar\u0131, y\u00fcksek volatilite ve hisse seyrelme riski bulunmaktad\u0131r."},{"question":"OVID hissesi i\u00e7in fiyat tahminleri nelerdir?","answer":"2025 y\u0131l sonu i\u00e7in fiyat tahmini 3,10-7,14 $ aral\u0131\u011f\u0131nda olup, uzun vadede ba\u015far\u0131l\u0131 ila\u00e7 onaylar\u0131 ile daha y\u00fcksek seviyelere ula\u015fabilir."},{"question":"Yeni ba\u015flayanlar OVID hissesi al\u0131rken nelere dikkat etmeli?","answer":"Portf\u00f6y\u00fcn k\u00fc\u00e7\u00fck bir y\u00fczdesiyle ba\u015flay\u0131n, dolar maliyeti ortalamas\u0131 yap\u0131n, stop-loss kullan\u0131n ve \u00f6nemli kataliz\u00f6r tarihlerini takip edin."}],"faq_source":{"label":"FAQ","type":"repeater","formatted_value":[{"question":"Ovid Therapeutics hisseleri nereden al\u0131nabilir?","answer":"Ovid Therapeutics hisseleri NASDAQ borsas\u0131nda i\u015flem g\u00f6rmektedir ve bir\u00e7ok \u00e7evrimi\u00e7i arac\u0131 kurum ve ticaret platformu \u00fczerinden sat\u0131n al\u0131nabilir."},{"question":"OVID hissesi almak i\u00e7in minimum yat\u0131r\u0131m tutar\u0131 nedir?","answer":"Minimum yat\u0131r\u0131m tutar\u0131 platforma g\u00f6re de\u011fi\u015fir ancak Pocket Option gibi baz\u0131 platformlarda sadece 5 $ depozito ile ba\u015flayabilirsiniz."},{"question":"Ovid Therapeutics hisselerinin riskleri nelerdir?","answer":"Ba\u015fl\u0131ca riskler aras\u0131nda nakit t\u00fcketimi, klinik deneme ba\u015far\u0131s\u0131zl\u0131klar\u0131, y\u00fcksek volatilite ve hisse seyrelme riski bulunmaktad\u0131r."},{"question":"OVID hissesi i\u00e7in fiyat tahminleri nelerdir?","answer":"2025 y\u0131l sonu i\u00e7in fiyat tahmini 3,10-7,14 $ aral\u0131\u011f\u0131nda olup, uzun vadede ba\u015far\u0131l\u0131 ila\u00e7 onaylar\u0131 ile daha y\u00fcksek seviyelere ula\u015fabilir."},{"question":"Yeni ba\u015flayanlar OVID hissesi al\u0131rken nelere dikkat etmeli?","answer":"Portf\u00f6y\u00fcn k\u00fc\u00e7\u00fck bir y\u00fczdesiyle ba\u015flay\u0131n, dolar maliyeti ortalamas\u0131 yap\u0131n, stop-loss kullan\u0131n ve \u00f6nemli kataliz\u00f6r tarihlerini takip edin."}]}},"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v24.8 (Yoast SEO v27.2) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Ovid Therapeutics Inc. (OVID) Hisseleri Nas\u0131l Al\u0131n\u0131r - Ovid Therapeutics Inc. (OVID) Hisse Senedi Yat\u0131r\u0131m\u0131<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-ovid-therapeutics\/\" \/>\n<meta property=\"og:locale\" content=\"tr_TR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Ovid Therapeutics Inc. (OVID) Hisseleri Nas\u0131l Al\u0131n\u0131r - Ovid Therapeutics Inc. (OVID) Hisse Senedi Yat\u0131r\u0131m\u0131\" \/>\n<meta property=\"og:description\" content=\"text\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-ovid-therapeutics\/\" \/>\n<meta property=\"og:site_name\" content=\"Pocket Option blog\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-25T12:50:53+00:00\" \/>\n<meta name=\"author\" content=\"Signal\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Yazan:\" \/>\n\t<meta name=\"twitter:data1\" content=\"Signal\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-ovid-therapeutics\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-ovid-therapeutics\/\"},\"author\":{\"name\":\"Signal\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\"},\"headline\":\"Ovid Therapeutics Inc. (OVID) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Ovid Therapeutics Inc. (OVID) Hisse Senedi Yat\u0131r\u0131m\u0131\",\"datePublished\":\"2025-08-25T12:50:53+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-ovid-therapeutics\/\"},\"wordCount\":21,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-ovid-therapeutics\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals15-scaled.webp\",\"keywords\":[\"signal\"],\"articleSection\":[\"Signals\"],\"inLanguage\":\"tr\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-ovid-therapeutics\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-ovid-therapeutics\/\",\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-ovid-therapeutics\/\",\"name\":\"Ovid Therapeutics Inc. (OVID) Hisseleri Nas\u0131l Al\u0131n\u0131r - Ovid Therapeutics Inc. (OVID) Hisse Senedi Yat\u0131r\u0131m\u0131\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-ovid-therapeutics\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-ovid-therapeutics\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals15-scaled.webp\",\"datePublished\":\"2025-08-25T12:50:53+00:00\",\"author\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\"},\"breadcrumb\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-ovid-therapeutics\/#breadcrumb\"},\"inLanguage\":\"tr\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-ovid-therapeutics\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"tr\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-ovid-therapeutics\/#primaryimage\",\"url\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals15-scaled.webp\",\"contentUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals15-scaled.webp\",\"width\":2560,\"height\":1429},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-ovid-therapeutics\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/pocketoption.com\/blog\/tr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Ovid Therapeutics Inc. (OVID) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Ovid Therapeutics Inc. (OVID) Hisse Senedi Yat\u0131r\u0131m\u0131\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#website\",\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/\",\"name\":\"Pocket Option blog\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/pocketoption.com\/blog\/tr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"tr\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\",\"name\":\"Signal\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"tr\",\"@id\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"caption\":\"Signal\"},\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/author\/signal\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Ovid Therapeutics Inc. (OVID) Hisseleri Nas\u0131l Al\u0131n\u0131r - Ovid Therapeutics Inc. (OVID) Hisse Senedi Yat\u0131r\u0131m\u0131","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-ovid-therapeutics\/","og_locale":"tr_TR","og_type":"article","og_title":"Ovid Therapeutics Inc. (OVID) Hisseleri Nas\u0131l Al\u0131n\u0131r - Ovid Therapeutics Inc. (OVID) Hisse Senedi Yat\u0131r\u0131m\u0131","og_description":"text","og_url":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-ovid-therapeutics\/","og_site_name":"Pocket Option blog","article_published_time":"2025-08-25T12:50:53+00:00","author":"Signal","twitter_card":"summary_large_image","twitter_misc":{"Yazan:":"Signal"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-ovid-therapeutics\/#article","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-ovid-therapeutics\/"},"author":{"name":"Signal","@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe"},"headline":"Ovid Therapeutics Inc. (OVID) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Ovid Therapeutics Inc. (OVID) Hisse Senedi Yat\u0131r\u0131m\u0131","datePublished":"2025-08-25T12:50:53+00:00","mainEntityOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-ovid-therapeutics\/"},"wordCount":21,"commentCount":0,"image":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-ovid-therapeutics\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals15-scaled.webp","keywords":["signal"],"articleSection":["Signals"],"inLanguage":"tr","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-ovid-therapeutics\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-ovid-therapeutics\/","url":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-ovid-therapeutics\/","name":"Ovid Therapeutics Inc. (OVID) Hisseleri Nas\u0131l Al\u0131n\u0131r - Ovid Therapeutics Inc. (OVID) Hisse Senedi Yat\u0131r\u0131m\u0131","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-ovid-therapeutics\/#primaryimage"},"image":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-ovid-therapeutics\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals15-scaled.webp","datePublished":"2025-08-25T12:50:53+00:00","author":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe"},"breadcrumb":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-ovid-therapeutics\/#breadcrumb"},"inLanguage":"tr","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-ovid-therapeutics\/"]}]},{"@type":"ImageObject","inLanguage":"tr","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-ovid-therapeutics\/#primaryimage","url":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals15-scaled.webp","contentUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals15-scaled.webp","width":2560,"height":1429},{"@type":"BreadcrumbList","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-ovid-therapeutics\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/pocketoption.com\/blog\/tr\/"},{"@type":"ListItem","position":2,"name":"Ovid Therapeutics Inc. (OVID) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Ovid Therapeutics Inc. (OVID) Hisse Senedi Yat\u0131r\u0131m\u0131"}]},{"@type":"WebSite","@id":"https:\/\/pocketoption.com\/blog\/tr\/#website","url":"https:\/\/pocketoption.com\/blog\/tr\/","name":"Pocket Option blog","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pocketoption.com\/blog\/tr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"tr"},{"@type":"Person","@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe","name":"Signal","image":{"@type":"ImageObject","inLanguage":"tr","@id":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","caption":"Signal"},"url":"https:\/\/pocketoption.com\/blog\/tr\/author\/signal\/"}]}},"po_author":null,"po__editor":null,"po_last_edited":null,"wpml_current_locale":"tr_TR","wpml_translations":{"vt_VT":{"locale":"vt_VT","id":347685,"slug":"how-to-buy-ovid-therapeutics","post_title":"C\u00e1ch mua c\u1ed5 phi\u1ebfu Ovid Therapeutics Inc. (OVID) - \u0110\u1ea7u t\u01b0 v\u00e0o c\u1ed5 phi\u1ebfu Ovid Therapeutics Inc. (OVID)","href":"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-ovid-therapeutics\/"},"pt_AA":{"locale":"pt_AA","id":347686,"slug":"how-to-buy-ovid-therapeutics","post_title":"Como comprar a\u00e7\u00f5es da Ovid Therapeutics Inc. (OVID) - Investimento em a\u00e7\u00f5es da Ovid Therapeutics Inc. (OVID)","href":"https:\/\/pocketoption.com\/blog\/pt\/news-events\/signal\/how-to-buy-ovid-therapeutics\/"}},"_links":{"self":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts\/347681","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/users\/129"}],"replies":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/comments?post=347681"}],"version-history":[{"count":1,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts\/347681\/revisions"}],"predecessor-version":[{"id":347682,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts\/347681\/revisions\/347682"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/media\/334117"}],"wp:attachment":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/media?parent=347681"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/categories?post=347681"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/tags?post=347681"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}